Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513.
Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS. Chiorean EG, et al. Among authors: pishvaian mj. Clin Cancer Res. 2021 Dec 1;27(23):6314-6322. doi: 10.1158/1078-0432.CCR-21-1789. Epub 2021 Sep 27. Clin Cancer Res. 2021. PMID: 34580114 Free PMC article.
Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL, Berger MS, Viallet J, Marshall JL. Hwang JJ, et al. Among authors: pishvaian mj. Clin Cancer Res. 2010 Aug 1;16(15):4038-45. doi: 10.1158/1078-0432.CCR-10-0822. Epub 2010 Jun 10. Clin Cancer Res. 2010. PMID: 20538761 Free PMC article. Clinical Trial.
A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD. Pishvaian MJ, et al. Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8. Cancer. 2012. PMID: 22570147 Free PMC article. Clinical Trial.
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, Deeken J, He AR, Hwang J, Malik S, Firozvi K, Liu M, Elston B, Strychor S, Egorin MJ, Marshall JL. Pishvaian MJ, et al. Cancer Chemother Pharmacol. 2012 Dec;70(6):843-53. doi: 10.1007/s00280-012-1969-9. Epub 2012 Sep 27. Cancer Chemother Pharmacol. 2012. PMID: 23014737 Free PMC article. Clinical Trial.
Postresection chemotherapy for pancreatic cancer.
Smaglo BG, Pishvaian MJ. Smaglo BG, et al. Among authors: pishvaian mj. Cancer J. 2012 Nov-Dec;18(6):614-23. doi: 10.1097/PPO.0b013e31827459d8. Cancer J. 2012. PMID: 23187850 Review.
PARP inhibitors for chemoprevention--letter.
Chand SN, Blanco FF, Jimbo M, Tsangaris TN, Cristofanilli M, Yeo CJ, Winter JM, Pishvaian MJ, Brody JR. Chand SN, et al. Among authors: pishvaian mj. Cancer Prev Res (Phila). 2014 Nov;7(11):1170-1. doi: 10.1158/1940-6207.CAPR-14-0220. Cancer Prev Res (Phila). 2014. PMID: 25368011 No abstract available.
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR. Gabrielson A, et al. Among authors: pishvaian mj. Cancer Chemother Pharmacol. 2015 Nov;76(5):1073-9. doi: 10.1007/s00280-015-2852-2. Epub 2015 Oct 8. Cancer Chemother Pharmacol. 2015. PMID: 26449224 Free PMC article. Clinical Trial.
106 results